We hypothesize that circulating soluble α‑Klotho, released from the kidney, directly protects cerebrovascular progenitor cells from phosphate‑driven mitochondrial dysfunction by scavenging intracellular ROS and restoring oxidative phosphorylation, a function that does not require its co‑receptor activity with FGF23.

Mechanistic Rationale

• α‑Klotho declines with age and correlates with progenitor cell mitochondrial impairment in renal tissue [1].
• Soluble α‑Klotho possesses intrinsic anti‑oxidative enzymes activities (e.g., β‑glucuronidase‑like) that can detoxify hydrogen peroxide and superoxide [3].
• Elevated serum phosphate, a hallmark of CKD and aging, induces ROS production in vascular progenitors, leading to senescence and impaired angiogenesis [2].
• In heart and liver, FGF23 signals via FGFRs independently of α‑Klotho, yet α‑Klotho amplifies FGFR binding twenty‑fold in kidney [3]; this suggests a tissue‑specific scaffolding role versus a systemic ligand role.
• Therefore, kidney‑derived soluble α‑Klotho may act as a circulating hormetin that mitigates phosphate toxicity in the brain vasculature without needing to modulate FGF23 signaling.

Testable Predictions

1. Administration of recombinant soluble α‑Klotho to aged mice with elevated serum phosphate will restore mitochondrial membrane potential and ATP production in isolated cerebral microvascular progenitors, whereas FGF23 neutralization will not alter this rescue.
2. Genetic deletion of α‑Klotho specifically in kidney tubules (but not in brain) will exacerbate phosphate‑induced ROS accumulation and reduce progenitor proliferation in the cerebral cortex, while global FGF23 knockout will not worsen the phenotype.
3. Pharmacological inhibition of mitochondrial ROS (e.g., with MitoTEMPO) will phenocopy the protective effect of soluble α‑Klotho, indicating ROS scavenging as a central mechanism.
4. In vitro, phosphate‑treated human iPSC‑derived cerebrovascular progenitors will show increased superoxide levels; co‑culture with conditioned medium from Klotho‑overexpressing kidney tubular cells will normalize ROS, an effect blocked by immunodepletion of soluble α‑Klotho from the medium.

Potential Experimental Approaches

• In vivo: Use kidney‑specific Klotho floxed mice crossed with Pax8‑CreERT2 to induce adult tubule deletion; monitor serum phosphate, cerebral microvascular progenitor markers (PDGFRβ+, CD133+) and mitochondrial function via JC‑1 staining and Seahorse analysis.
• Ex vivo: Isolate cerebral microvascular fragments from young and old mice, treat with recombinant Klotho ± FGF23 neutralizing antibody, measure ROS with MitoSOX and oxygen consumption rate.
• In vitro: Differentiate human iPSCs into vascular progenitors, expose to high phosphate (1.8 mM), add conditioned medium from HEK293 cells secreting soluble Klotho; assess mitochondrial ROS, ATP, and tube formation on Matrigel.
• Readouts: Mitochondrial membrane potential, ATP production, ROS levels, progenitor proliferation (Ki‑67), senescence (β‑gal), and functional angiogenesis.

If these predictions hold, the kidney‑brain axis of the Klotho system would be redefined as a phosphate‑ROS detoxification pathway, independent of the classical FGF23 endocrine loop, opening therapeutic avenues for cerebrovascular aging that target Klotho supplementation rather than FGF23 antagonism.